Radyx Bio is developing CG1.4, an oral botanical therapy for rheumatoid arthritis designed to regulate the immune system rather than suppress it, addressing the low remission rates and safety concerns of current standard-of-care treatments. The company's lead candidate emerged from a proprietary plant-based medicine selection process backed by five human clinical trials showing statistically significant efficacy.
Funding
Funding not disclosed
Founders
Product
Problem
Current standard-of-care options for rheumatoid arthritis leave millions of patients without lasting relief. Remission rates remain low (30–40%), and drug efficacy often diminishes over time—leading nearly half of all patients to discontinue their treatment. Even among those on active therapy, 74% continue to report uncontrolled pain and fatigue, while existing treatments carry severe immunosuppressive risks, FDA boxed warnings, high costs, and the inconvenience of injectable biologics.
Solution
Radyx Bio is advancing CG1.4, an oral botanical therapy designed to regulate the immune system rather than suppress it, offering a potentially safer and more tolerable alternative for rheumatoid arthritis patients. The therapy is built on a proprietary plant-based medicine selection process that optimizes botanical compounds for complex disease targets, with the lead asset backed by ten validated research studies including five human clinical trials demonstrating statistically significant efficacy. This approach aims to overcome the efficacy gaps, safety concerns, and administration burdens of current injectable biologics and immunosuppressive drugs.
Target Audience
The primary audience is rheumatoid arthritis patients who have not achieved lasting remission or who experience intolerable side effects from current immunosuppressive therapies, along with rheumatologists seeking safer, oral, and better-tolerated treatment options.
Features
- CG1.4 oral therapy designed to modulate rather than suppress immune function, potentially reducing immunosuppressive risks
- Proprietary botanical selection process for optimizing plant-based medicines against complex disease targets
- Backed by ten validated research studies including five human clinical trials, four in vitro bioassays, and a lab study, all showing statistically significant efficacy
- Four issued U.S. patents covering immune function and related therapeutic applications
- Established botanical supply chain and manufacturing infrastructure capable of sourcing and producing concentrated plant-based extracts at scale
- Regulatory pathway supported by expertise in FDA Botanical Drug Guidance, with prior experience guiding Botanical New Drug approvals